Same Indication

Nivolumab vs Sars-Cov-2 Virus Spike Protein

Nivolumab vs Sars-Cov-2 Virus Spike Protein: Overview

This comparison examines the pharmacological differences between Nivolumab and Sars-Cov-2 Virus Spike Protein.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Nivolumab β€” 27 days.

Chemical Properties

Type: Nivolumab β€” Antibody; Sars-Cov-2 Virus Spike Protein β€” Vaccine component.